MedTrace Logo

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

NCT00725387 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 214

Last updated 2019-09-18

No results posted yet for this study

Summary

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Conditions

  • Neoplasms

Sponsors & Collaborators

Principal Investigators

  • Andrei Iagaru M.D · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2018-12-31
Completion
2019-06-30

Countries

  • United States
  • Denmark
  • India
  • Portugal
  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00725387 on ClinicalTrials.gov